FORM 8.3

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY
A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE
Rule 8.3 of the Takeover Code (the “Code”)

1.        KEY INFORMATION

(a)   Full name of discloser: Davidson Kempner Capital Management LP
(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):
        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.
 
(c)   Name of offeror/offeree in relation to whose relevant securities this form relates:
        Use a separate form for each offeror/offeree
Tate & Lyle plc
(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:  
(e)   Date position held/dealing undertaken:
        For an opening position disclosure, state the latest practicable date prior to the disclosure
01/10/2026
(f)   In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?
        If it is a cash offer or possible cash offer, state “N/A”
 

2.        POSITIONS OF THE PERSON MAKING THE DISCLOSURE

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

(a)      Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

Class of relevant security: 29 1/6p ordinary
  Interests Short positions
Number % Number %
(1)   Relevant securities owned and/or controlled:        
(2)   Cash-settled derivatives: 15,481,929 3.47%    
(3)   Stock-settled derivatives (including options) and agreements to purchase/sell:        
        TOTAL: 15,481,929 3.47%    

All interests and all short positions should be disclosed.

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

(b)      Rights to subscribe for new securities (including directors’ and other employee options)

Class of relevant security in relation to which subscription right exists:  
Details, including nature of the rights concerned and relevant percentages:  

3.        DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a)        Purchases and sales

Class of relevant security Purchase/sale Number of securities Price per unit

(b)        Cash-settled derivative transactions

Class of relevant security Product description
e.g. CFD
Nature of dealing
e.g. opening/closing a long/short position, increasing/reducing a long/short position
Number of reference securities Price per unit
29 1/6p ordinary CFD Increasing a long position 1,401,300 GBP 5.5850

(c)        Stock-settled derivative transactions (including options)

(i)        Writing, selling, purchasing or varying

Class of relevant security Product description e.g. call option Writing, purchasing, selling, varying etc. Number of securities to which option relates Exercise price per unit Type
e.g. American, European etc.
Expiry date Option money paid/ received per unit

(ii)        Exercise

Class of relevant security Product description
e.g. call option
Exercising/ exercised against Number of securities Exercise price per unit

(d)        Other dealings (including subscribing for new securities)

Class of relevant security Nature of dealing
e.g. subscription, conversion
Details Price per unit (if applicable)

4.        OTHER INFORMATION

(a)        Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:
Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none”
 

(b)        Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:
(i)   the voting rights of any relevant securities under any option; or
(ii)   the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:
If there are no such agreements, arrangements or understandings, state “none”
 

(c)        Attachments

Is a Supplemental Form 8 (Open Positions) attached? NO

Date of disclosure: 02/10/2026
Contact name: Alex McMillan
Telephone number: 646 282 5805

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.

FORM 8.3

IRISH TAKEOVER PANEL

OPENING POSITION DISCLOSURE/DEALING DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER
RULES, 2022 BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

1.      KEY INFORMATION

(a)   Full name of discloser Davidson Kempner Capital Management LP
(b)   Owner or controller of interests and short positions disclosed, if different from 1(a)
The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.
 
(c)   Name of offeror/offeree in relation to whose relevant securities this form relates
Use a separate form for each offeror/offeree
DCC plc
(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree (Note 1)  
(e)   Date position held/dealing undertaken
For an opening position disclosure, state the latest practicable date prior to the disclosure
01/10/2026
(f)   In addition to the company in 1(c) above, is the discloser also making disclosures in respect of any other party to the offer?
If it is a cash offer or possible cash offer, state “N/A”
No

2.      INTERESTS AND SHORT POSITIONS

If there are interests and short positions to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2 for each additional class of relevant security.

Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)
(Note 2)

Class of relevant security
(Note 3)
€0.25 Ordinary Shares
(ISIN – IE0002424939)
  Interests Short positions
Number % Number %
(1)   Relevant securities owned and/or controlled        
(2)   Cash-settled derivatives 856,074 1.00%    
(3)   Stock-settled derivatives (including options) and agreements to purchase/ sell        
Total 856,074 1.00%    

All interests and all short positions should be disclosed.

Details of options including rights to subscribe for new securities and any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8.

3.      DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE (Note 4)

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a)      Purchases and sales

Class of relevant
security
Purchase/sale Number of
securities
Price per unit
(Note 5)

(b)      Cash-settled derivative transactions

Class of
relevant
security
Product
description
e.g. CFD
Nature of dealing Number of
reference
securities
(Note 6)
Price
per unit

€0.25 Ordinary Shares CFD Reducing a long position 37,680 GBP 64.4000

(c)      Stock-settled derivative transactions (including options)

(i)      Writing, selling, purchasing or varying

Class of
relevant
security
Product
description e.g. call
option
Writing, purchasing, selling, varying
etc.
Number
of
securities
to which
option
relates
(Note 6)
Exercise
price per
unit
Type
e.g.
American,
European
etc.
Expiry
date
Option
money
paid/
received per unit

(ii)      Exercise

Class of
relevant
security
Product
description
e.g. call
option
Exercising/
exercised
against
Number of
securities
Exercise
price per
unit
(Note 5)

(d)      Other dealings (including transactions in respect of new securities) (Note 3)

Class of
relevant
security
Nature of dealing
e.g. subscription,
conversion, exercise
Details Price per unit (if
applicable)
(Note 5)

4.      OTHER INFORMATION

(a)      Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer.
Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none”
 

(b)      Agreements, arrangements or understandings relating to options or derivatives

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.
 

(c)        Attachments

Is a Supplemental Form 8 attached? NO

Date of disclosure 02/10/2026
Contact name Alex McMillan
Telephone number 646 282 5805

Public disclosures under Rule 8.3 of the Rules must be made to a Regulatory Information Service.

NOTES ON FORM 8.3

1.      See the definition of “connected fund manager” in Rule 2.2 of Part A of the Rules.

2.      See the definition of “interest in a relevant security” in Rule 2.5 of Part A of the Rules and see Rule 8.6(a) and (b) of Part B of the Rules.

3.      See the definition of “relevant securities” in Rule 2.1 of Part A of the Rules.

4.      See the definition of “dealing” in Rule 2.1 of Part A of the Rules.

5.      If the economic exposure to changes in the price of securities is limited, for example, by virtue of a stop loss arrangement relating to a spread bet, full details must be given.

6.      See Rule 2.5(d) of Part A of the Rules.

7.      If details included in a disclosure under Rule 8 are incorrect, they should be corrected as soon as practicable in a subsequent disclosure. Such disclosure should state clearly that it corrects details disclosed previously, identify the disclosure or disclosures being corrected, and provide sufficient detail for the reader to understand the nature of the corrections. In the case of any doubt, the Panel should be consulted.

For full details of disclosure requirements, see Rule 8 of the Rules. If in doubt, consult the Panel.

References in these notes to “the Rules” are to the Irish Takeover Panel Act, 1997, Takeover Rules, 2022.

Bid procedure, 2026-10-09
Bonds SWEDEN I/L BOND: 3113. SE0009548704. 2027-12-01
SWEDEN I/L BOND: 3104, SE0000556599, 2028-12-01
Bid date 2026-10-09
Bid times 09.00-10.00 (CET/CEST) on the Bid date
Offered volume (corresponding nominal amount) 3113: 250 million SEK +/-250 million SEK
3104: 150 million SEK +250/-150 million SEK
Highest permitted bid volume (corresponding nominal amount) 3113: 250 million SEK per bid
3104: 150 million SEK per bid
Lowest permitted bid volume (corresponding nominal amount) SEK 10 million per bid
Expected allocation time Not later than 10.15 (CET/CEST) on the Bid date
Delivery and payment date 2026-10-13
Settlement amount To be paid to the Riksbank’s account in Euroclear Sweden AB’s securities settlement system SWIFT: VPCSSESSXXX Account: 1 4948 6383 CTM BIC: RIKSSESS ALERT acronym: RIKSBANK

Stockholm, 2026-10-02

This is a translation of the special terms and conditions published on www.riksbank.se. In the case of any inconsistency between the English translation and the Swedish language version, the Swedish language version shall prevail. Complete terms and conditions can be retrieved at www.riksbank.se.

ZUG, Switzerland and BOSTON, Oct. 02, 2026 (GLOBE NEWSWIRE) — CRISPR Therapeutics (Nasdaq: CRSP), today announced that a poster presentation highlighting the Company’s Phase 1 clinical data of its investigational CRISPR/Cas9 gene-edited allogeneic CAR T cell therapy, zugocabtagene geleucel (zugo-cel) targeting CD19 for autoimmune disease, will be presented at the American College of Rheumatology (ACR) Convergence 2026.

Title: Safety and Efficacy of Anti-CD19 Allogeneic Chimeric Antigen Receptor (CAR) T Cell Therapy Zugocabtagene Geleucel (zugo-cel) in Patients with Refractory Systemic Sclerosis
Session Type: Poster Presentation
Abstract Number: 0225
Session Name: Poster Session A
Date and Time: Sunday, November 8, 2026, 10:30 a.m. ET

Zugo-cel is being evaluated in Phase 1 trials across autoimmune diseases, including rheumatologic, hematologic and neurologic indications.

A copy of the presentation will be available at www.crisprtx.com once the presentation concludes.

About CRISPR Therapeutics
CRISPR Therapeutics is a leading biopharmaceutical company focused on developing transformative gene-based medicines for serious human diseases. Founded over a decade ago as an early pioneer in CRISPR/Cas9 gene editing, the Company has evolved from a pioneering research-stage organization into an industry leader, marking a historic milestone with the approval of CASGEVY® (exagamglogene autotemcel [exa-cel]), the world’s first CRISPR-based therapy, for eligible patients with sickle cell disease and transfusion-dependent beta thalassemia. Today, CRISPR Therapeutics is advancing a broad, diversified pipeline spanning hemoglobinopathies, cardiovascular disease, autoimmune disease, oncology, regenerative medicine and rare diseases. The Company is also expanding its gene editing toolkit through SyNTase™ editing, its novel, proprietary platform designed to enable precise, efficient, and scalable gene correction. To accelerate its impact, CRISPR Therapeutics has established strategic collaborations with leading biopharmaceutical partners, including Vertex Pharmaceuticals. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Boston, Massachusetts and San Francisco, California. To learn more, visit www.crisprtx.com.

CRISPR THERAPEUTICS® standard character mark and design logo and SyNTase™ are trademarks and registered trademarks of CRISPR Therapeutics AG. CASGEVY® and the CASGEVY logo are registered trademarks of Vertex Pharmaceuticals Incorporated. All other trademarks and registered trademarks are the property of their respective owners. 

CRISPR Therapeutics Forward-Looking Statement
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding any or all of the following: (i) CRISPR Therapeutics preclinical studies, clinical trials and pipeline products and programs, including, without limitation, manufacturing capabilities, status of such studies and trials and expectations regarding data, safety and efficacy generally; (ii) data included in the above-described poster presentation and any associated abstract; and (iii) the therapeutic value, development, and commercial potential of gene editing technologies and therapies, including CRISPR/Cas9, as well as other technologies. Risks that contribute to the uncertain nature of the forward-looking statements include, without limitation, the risks and uncertainties discussed under the heading “Risk Factors” in CRISPR Therapeutics most recent annual report on Form 10-K and in any other subsequent filings made by CRISPR Therapeutics with the U.S. Securities and Exchange Commission. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date they are made. We disclaim any obligation or undertaking to update or revise any forward-looking statements contained in this press release, other than to the extent required by law.

Investor Contact: 
+1-617-307-7503 
ir@crisprtx.com

Media Contact: 
 +1-617-315-4493 
media@crisprtx.com

A universal boost for today’s systems that delivers the speed tomorrow’s networks demand

FORTITUDE_image

Close up image of patented FORTITUDE™ multilayer chip technology. (Photo: Northrop Grumman)

BALTIMORE, Oct. 02, 2026 (GLOBE NEWSWIRE) — (PHOTO RELEASE): Designed to solve one of the hardest problems in modern electronics — moving massive amounts of information quickly, cleanly and reliably — Northrop Grumman’s FORTITUDE™ processes vast portions of the electromagnetic spectrum on a single, grain-of-rice–sized gallium nitride chip. The future-ready technology delivers three times more power and 20 times better signal quality, helping satellites, radar, GPS, electronic warfare and future 6G systems stay connected with clearer, more reliable performance.

Previously known as the Super Lattice Castellated Field Effect Transistor, FORTITUDE™ builds on the company’s focused research and development and substantial investment in microelectronics to replace dozens of components, cutting weight, and slashing power consumption while delivering greater value for the end system. Built in the U.S. for both commercial and defense markets, FORTITUDE™ simplifies system architectures and opens new opportunities for faster, more dependable communications across next generation platforms.

Learn more about Northrop Grumman’s FORTITUDE™ here.

Contact:  Leslie Zychowski
410-218-1395 
leslie.zychowski@ngc.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/083cc2e0-2715-47d9-8c66-9c3490a61eb5

DENVER, Oct. 02, 2026 (GLOBE NEWSWIRE) — SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transformational treatments for critically ill patients facing organ failure and potential loss of life announced today that a late-breaking abstract evaluating the results of the post-approval SAVE Registry data has been accepted for a special late-breaker poster presentation at the upcoming American Society of Nephrology (ASN) Kidney Week 2026 meeting, taking place in Denver, CO, October 21 – 25, 2026.

Presentation Details:

Title: Improved Outcomes in Pediatric Sepsis-Associated (SA) AKI: Comparison of the Selective Cytopheretic Device for Pediatrics (SCD-PED) Surveillance Registry (SAVE) with a Historical Cohort

Authors: Nathan L. Kleinman, Stuart Goldstein, Rajit K. Basu, Theresa A. Mottes, David J. Askenazi, Stephen Gorga, Shina Menon, Matt S. Zinter, Keri A. Drake, David A. Zolezzi, Robert S. Gillespie, Sai Prasad N. Iyer, Emily Scribe, Kevin K. Chung

Abstract / Poster Number: TH-PO1291

Date & Time: October 22, 2026, from 10:00 a.m. to 12:00 p.m. MT

Location: Exhibit Hall A, Colorado Convention Center

About SeaStar Medical

SeaStar Medical is a commercial-stage healthcare company focused on transformational treatments for critically ill patients facing organ failure and potential loss of life. SeaStar Medical’s first commercial product, QUELIMMUNE (SCD-PED), was approved in 2024 by the U.S. Food and Drug Administration (FDA). It is the only FDA approved product for the ultra-rare condition of life-threatening Acute Kidney Injury (AKI) due to sepsis or a septic condition requiring renal replacement therapy (RRT) in critically ill pediatric patients. SeaStar Medical’s Selective Cytopheretic Device (SCD) therapy has been awarded Breakthrough Device Designation for six therapeutic indications by the FDA, enabling the potential for a speedier pathway to approval and preferable reimbursement dynamics at commercial launch. The company is currently conducting the NEUTRALIZE-AKI pivotal clinical trial of its SCD therapy in adult patients with AKI requiring continuous renal replacement therapy, a life-threatening condition with no effective treatment options that impacts over 200,000 adults in the U.S. annually.

For more information visit www.seastarmedical.com or visit us on LinkedIn or X.

Contact:  
IR@SEASTARMED.COM

QUELIMMUNE is a registered trademark of SeaStar Medical Holding Corporation.

Preliminary Phase 2 data from the ongoing PrisMN study of budoprutug in primary membranous nephropathy selected for oral presentation

Presentations on CLYM116 and budoprutug programs highlight advancements across the portfolio

WELLESLEY HILLS, Mass., Oct. 02, 2026 (GLOBE NEWSWIRE) — Climb Bio, Inc. (Nasdaq: CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced that it will present new clinical data for its CLYM116 and budoprutug programs across three immune-mediated kidney diseases at the American Society of Nephrology (ASN) Kidney Week 2026, which will be held in Denver, Colorado from October 21-25, 2026.

Abstracts are available on the ASN 2026 website here.

Posters and Presentations

CLYM116

Title: CLYM116, a Novel “Sweeper” Anti-A PRoliferation-Inducing Ligand Monoclonal Antibody in Development for IgAN: Phase 1 Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) Results in Healthy Volunteers
Session Title: Pharmacology (PharmacoKinetics, -Dynamics, -Genomics) [PO1900]
Poster Number: TH-PO0823
Date / Time: October 22, 2026, from 10:00 AM to 12:00 p.m. MT

Title: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MIL116, a Novel “Sweeper” Anti-A PRoliferation-Inducing Ligand Monoclonal Antibody in Healthy Volunteers: Preliminary Phase 1 Results
Session Title: Glomerular Diseases: Practice and New Concepts Shaping Modern Care [PO1402-06]
Poster Number: FR-PO0838
Date / Time: October 23, 2026, from 10:00 AM to 12:00 p.m. MT

Budoprutug

Title: Preliminary Data from PrisMN, a Phase 2 Study Evaluating the Safety and Efficacy of Budoprutug, an Investigational Low-Fucosylated Anti-CD19 Monoclonal Antibody (mAb), in Patients with Primary Membranous Nephropathy (PMN)
Session Title: Glomerular Diseases: Clinical Trial Results [OR1402-3]
Session Room: Mile High Ballroom 4A (Convention Center)
Date / Time: October 24, 2026, from 5:30 PM to 5:40 p.m. MT

Title: Budoprutug for Minimal Change Disease (MCD): A Case Study of Durable Response and Potential Disease Modification via CD19+ B-Cell Depletion
Session Title: Glomerular Diseases: Membranous Nephropathy, FSGS, and Podocytopathies [PO1402-04]
Poster Number: FR-PO0713
Date / Time: October 23, 2026, from 10:00 AM to 12:00 p.m. MT

About Climb Bio, Inc.
Climb Bio, Inc. is a clinical-stage biotechnology company with a mission to deliver high impact, disease-modifying medicines for individuals living with immune-mediated diseases, including those affecting kidney health. The Company’s pipeline includes, budoprutug, an anti-CD19 monoclonal antibody that has potential to treat a broad range of B-cell mediated diseases, and CLYM116, an anti-APRIL monoclonal antibody being developed for IgA nephropathy. For more information, please visit climbbio.com.

About CLYM116
CLYM116 is a clinical-stage monoclonal antibody targeting APRIL (A Proliferation-Inducing Ligand), a key driver of pathogenic B-cell activity in autoimmune diseases. CLYM116 employs a novel pH-dependent bind-and-release ‘sweeper’ mechanism to potently block APRIL signaling, promote lysosomal degradation of APRIL, and recycle the antibody to extend its half-life. This differentiated design offers the potential for rapid, deep, and durable inhibition of APRIL with a favorable safety profile and less frequent dosing. CLYM116 is being advanced for the treatment of IgA nephropathy (IgAN) and may also have broader utility across other B-cell mediated diseases where APRIL plays a critical role.

About Budoprutug
Budoprutug is a clinical-stage, anti-CD19 monoclonal antibody with the potential to address a broad range of B-cell mediated, immune-driven diseases. Designed with enhanced effector function and low picomolar affinity, budoprutug targets and depletes CD19-expressing B cells, including plasmablasts and certain plasma cells, key sources of pathogenic autoantibodies. Early clinical data suggest budoprutug may offer durable B-cell depletion, rapid reductions in autoantibodies, and clinical remission in primary membranous nephropathy (pMN). Budoprutug is being evaluated in clinical trials for pMN, immune thrombocytopenia (ITP), and systemic lupus erythematosus (SLE). A subcutaneous formulation is also in development to enable broader patient access. Budoprutug has been granted Orphan Drug Designation and Fast Track Designation by the FDA for the treatment of pMN.

Forward-Looking Statements
This press release contains “forward-looking statements” including without limitation statements regarding: expectations regarding the therapeutic benefits, clinical potential and clinical development of CLYM116 and budoprutug; the anticipated timelines for announcing data from Climb Bio’s ongoing and planned clinical trials; and other statements containing the words “anticipate,” “believe,” “continue,” “could,” “expect,” “may,” “plan,” “potential,” “suggest,” “target,” “will” and similar expressions. Forward-looking statements are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in, or implied by, such forward-looking statements. Climb Bio may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. These risks and uncertainties include, but are not limited to, important risks and uncertainties associated with: the ability of Climb Bio to timely and successfully achieve or recognize the anticipated benefits of its acquisition of Tenet Medicines, Inc. and its technology transfer and exclusive license agreement with Mabworks; Climb Bio’s ability to advance budoprutug and CLYM116 on the timelines expected or at all and to obtain and maintain necessary approvals from the U.S. Food and Drug Administration and other regulatory authorities; obtaining and maintaining the necessary approvals from investigational review boards at clinical trial sites and independent data safety monitoring boards; replicating in clinical trials positive results found in early-stage clinical trials or nonclinical studies; competing successfully with other companies that are seeking to develop treatments for primary membranous nephropathy, immune thrombocytopenia, systemic lupus erythematosus, IgA nephropathy and other immune-mediated diseases; maintaining or protecting intellectual property rights related to budoprutug, CLYM116 and/or its other product candidates; managing expenses; changes in applicable laws or regulation; the possibility that Climb Bio may be adversely affected by other economic, business and/or competitive factors; and raising the substantial additional capital needed, on the timeline necessary, to continue development of budoprutug, CLYM116 and any other product candidates Climb Bio may develop. For a discussion of other risks and uncertainties, and other important factors, any of which could cause Climb Bio’s actual results to differ materially from those contained in the forward-looking statements, see the “Risk Factors” section, as well as discussions of potential risks, uncertainties and other important factors, in Climb Bio’s most recent filings with the U.S. Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent Climb Bio’s views as of the date hereof and should not be relied upon as representing Climb Bio’s views as of any date subsequent to the date hereof. Climb Bio anticipates that subsequent events and developments will cause Climb Bio’s views to change. However, while Climb Bio may elect to update these forward-looking statements at some point in the future, Climb Bio specifically disclaims any obligation to do so, except as required by law.

Investors and Media
Carlo Tanzi, Ph.D.
Kendall Investor Relations
ctanzi@kendallir.com

AS LHV Group announces that during the period 25 September to 1 October 2026, it has acquired the company’s own shares on the Nasdaq Tallinn Stock Exchange as follows: 

Date  Aggregated volume (pcs)  Weighted average price per day (EUR) 
25.09.2026 13,400 3.29
28.09.2026 26,800 3.2875
29.09.2026 18,033 3.283659957
30.09.2026 26,400 3.2725
01.10.2026 26,800 3.2675

 
LHV Group is acquiring its own shares based on the resolution of the company’s general meeting of shareholders held on 26 March 2025, and under the conditions decided by the Supervisory Board. The authorized agent for the transactions is AS LHV Pank. Summary data of the acquisitions will be disclosed no later than on the seventh trading day after the transaction and will be made available to the Financial Supervision and Resolution Authority, via the Nasdaq Tallinn system, and on LHV Group’s investor website. 

LHV Group is the largest domestic financial group and capital provider in Estonia. LHV Group’s main subsidiaries are LHV Pank, LHV Varahaldus, LHV Kindlustus and LHV Bank Limited. The Group employs nearly 1,200 people. LHV’s banking services are used by more than 514,000 customers, LHV-managed II pillar pension funds have 105,000 active customers and LHV Kindlustus provides insurance protection to 244,000 customers. LHV Bank, a subsidiary of LHV Group, holds a UK banking licence and offers banking services to international financial technology companies, loans to small and medium-sized enterprises and retail banking services.

 
Investor Relations 
Sten Hans Jakobsoo 
Head of Investor Relations and Corporate Development 
Email: stenhans.jakobsoo@lhv.ee 

Communications 
Paul Pihlak 
Head of Communications 
Email: paul.pihlak@lhv.ee  

Key Highlights

  • Leveraged Bitcoin Treasury: Matador holds approximately 168 Bitcoin and funds its treasury through a combination of common equity and secured convertible debt.
  • Convertible Note Facility: Matador has issued US$10.5 million principal amount of senior secured convertible notes under its US$100 million secured convertible note facility. The remaining US$89.5 million may be drawn in follow on closings, subject to regulatory approvals and other conditions.
  • Capital Markets Tools: Since November 2025, the Company has put in place a C$80 million base shelf prospectus and, qualified under that shelf, a C$30 million at the market equity program, and amended its secured convertible note facility to expand at the market capacity. Shareholders will be asked to approve a new class of preferred shares on October 14, 2026.
  • Cost Optimization: Management estimates that the Company’s cash operating expenditures currently average approximately C$125,000 per month, although monthly amounts vary, and that it continues to work toward a target of approximately C$100,000 per month, compared with average monthly net cash used in operating activities of approximately C$445,000 in the fiscal year ended October 31, 2025.
  • Leadership: Donato Sferra was appointed Chief Executive Officer and Deven Soni was appointed Executive Chairman, each effective July 16, 2026.

TORONTO, Oct. 02, 2026 (GLOBE NEWSWIRE) — Matador Technologies Inc. (“Matador” or the “Company”) (TSXV:MATA)(OTCQB:MATAF)(FSE:IU3), the Bitcoin Ecosystem Company, today provided a corporate update summarizing developments in its capital structure, operations and governance since the beginning of its 2026 fiscal year on November 1, 2025.

During that period, the Company issued US$10.5 million principal amount of senior secured convertible notes under a US$100 million facility and used the proceeds to acquire 92 Bitcoin, established a C$80 million base shelf prospectus and a C$30 million at the market equity program qualified under that shelf, and reduced its cash operating expenditures to a current estimated average of approximately C$125,000 per month, with a target of approximately C$100,000 per month. Matador holds approximately 168 Bitcoin as its primary treasury asset. All dollar figures in this news release are stated in Canadian dollars unless otherwise indicated.

Bitcoin Treasury and Capital Structure

As at the date of this news release, Matador holds approximately 168 Bitcoin as its primary treasury asset, with approximately 138 Bitcoin held as collateral under the Company’s US$100 million secured convertible note facility (the “Facility”) and the senior secured convertible notes issued under it (the “Notes”).

Matador is structured as a leveraged Bitcoin treasury company that funds its Bitcoin holdings through a combination of common equity and secured convertible debt. Because a portion of the Company’s Bitcoin was acquired with borrowed capital, a change in the price of Bitcoin can have a proportionally larger effect on the Company’s net asset value attributable to common shareholders than on the value of the Bitcoin itself. This effect operates in both directions and can magnify losses as well as gains. The actual effect in any period will depend on factors including the Company’s operating costs, the cost of its debt and any issuances of common shares. The market price of the Company’s common shares may not reflect its net asset value at any given time.

Capital Markets Framework

The Company has assembled a set of capital markets tools intended to allow it to raise capital efficiently and to acquire additional Bitcoin when management considers that market conditions and its cost of capital make doing so accretive to Bitcoin held per share, while retaining the flexibility not to issue securities when they do not.

On December 22, 2025, the Ontario Securities Commission issued a final receipt for the Company’s C$80 million short form base shelf prospectus, which is effective for 25 months from that date. On February 3, 2026, the Company established an at the market equity program (the “ATM Program”) pursuant to an equity distribution agreement with ATB Cormark Capital Markets, permitting the Company to offer and sell common shares for aggregate gross proceeds of up to C$30 million at prevailing market prices on the TSX Venture Exchange (the “Exchange”). From the commencement of the ATM Program on February 4, 2026 to October 1, 2026:

  • Common shares issued: 49,054,400
  • Weighted average price per share: $0.0478
  • Aggregate gross proceeds: $2,343,564.35
  • Net proceeds: $2,233,171.24

Net proceeds from the ATM Program have been used for the purchase of Bitcoin, in support of the Company’s Bitcoin yield generation strategy, and for general working capital purposes.

The Facility has been amended twice during the period. A waiver and amendment agreement dated February 3, 2026 permitted the ATM Program under the terms of the Facility. Amendment No. 2, announced on August 17, 2026, introduced an alternative definition of a permitted at the market offering which, prior to any listing on a US senior exchange, removes the aggregate proceeds cap, pricing floor and daily volume limitations that previously applied to at the market issuances conducted under the Company’s Canadian shelf prospectus documents. In exchange, an amount equal to 10 percent of the net proceeds of each qualifying sale is applied to the purchase of Bitcoin, which is deposited as additional collateral under the Facility.

Proposed Preferred Share Class

As announced by the Company on August 28, 2026, the Exchange conditionally accepted, on August 25, 2026, a proposed amendment to the Company’s articles to create a new class of an unlimited number of preferred shares (the “Preferred Shares”). The amendment is presented to shareholders as Resolution #5 in the Company’s management information circular, and shareholder approval will be requested at the annual general and special meeting of shareholders to be held on October 14, 2026. The amendment remains subject to that approval and to final acceptance by the Exchange.

The Company has no current plans to issue Preferred Shares. Certain larger Bitcoin treasury companies, including Strategy Inc. (NASDAQ: MSTR), have used preferred equity as part of their capital structures, and the Company considers it prudent to have that option available. Because an amendment to the Company’s articles requires shareholder approval, which is ordinarily sought at the Company’s annual meeting, the Company will request that approval at the October 14, 2026 meeting so that the board of directors will have the flexibility to consider preferred equity in the future, should circumstances warrant, without waiting for a subsequent annual meeting. Any future issuance of Preferred Shares would require the approval of the board of directors and specific approval of the Exchange.

Cost Optimization and Operating Efficiency

Since the beginning of fiscal 2026, the Company has reviewed its operating cost structure and implemented several measures to reduce costs and improve efficiency. The Company has restructured its executive and consulting agreements and terminated certain consulting engagements that were no longer considered necessary. The Company has also adopted artificial intelligence based tools internally to automate certain tasks and to perform work that was previously carried out by external advisors, allowing more of its finance, reporting and administrative functions to be completed internally on a more efficient basis.

As a result of these measures, management estimates that the Company’s cash operating expenditures currently average approximately C$125,000 per month. This figure is an unaudited management estimate, is not a measure recognized under IFRS, and may vary from month to month, including as a result of non-recurring professional fees and costs associated with the Company’s financing activities. By comparison, net cash used in operating activities for the fiscal year ended October 31, 2025, as reported in the Company’s audited annual financial statements, was C$5,337,072, or an average of approximately C$445,000 per month. Expenditures in that period reflected the cost of establishing Matador as a public issuer and building the capital markets framework now available to it, including the reverse takeover completed on December 9, 2024, the Company’s change of business to a hybrid issuer and the professional work required to put its shelf prospectus and equity distribution arrangements in place. The Company continues to review its cost structure on a continuous basis and to look for further opportunities to operate more leanly, with the objective of reducing average monthly cash operating expenditures to approximately C$100,000. Management intends to continue optimizing the Company’s cost base beyond the reductions achieved to date, although there can be no assurance as to the amount or timing of any further reductions. Management’s objective is a lean, low cost treasury company with a durable long term business model that is better positioned to maintain its Bitcoin position through periods of price volatility.

Bitcoin Yield Generation and GODL, a Gold Asset Treasury Company

Matador conducts a Bitcoin yield generation strategy in collaboration with Galaxy Digital Holdings Ltd. (“Galaxy”) pursuant to an ISDA Agreement, principally through the systematic execution of covered calls, alongside other supplementary options and yield generation strategies facilitated by Galaxy. Premium income from the strategy is not dependent on an increase in the price of Bitcoin, although Bitcoin allocated to the strategy remains exposed to price movements and may be called away at strike prices below prevailing market prices. Premium income varies with market conditions, and there can be no assurance as to the amount of premium income in any future period.

GODL is being organized as a pure-play gold treasury company. GODL intends to acquire physical gold and gold-backed tokens and to measure its progress principally by reference to gold ounces per share (“GOPS”), being gold ounces held divided by fully diluted shares outstanding. GODL also intends to pursue a gold yield strategy, principally through specialist gold leasing, the writing of covered calls and, as that market develops, the lending of tokenized gold, with the objective of generating a positive net yield after costs that would be reinvested in additional gold in order to increase GOPS over time. There can be no assurance that GODL will generate a positive net yield in any period.

Matador has developed technology for the tokenization of gold and intends to monetize that technology by licensing it to GODL. Matador and GODL have negotiated a form of licence agreement (the “Licence”) under which GODL would be permitted to use Matador’s gold tokenization intellectual property to create, issue and manage tokenized gold products. The Licence has not been executed and its terms remain subject to change.

Under the arrangement as currently contemplated, Matador would receive a combination of cash consideration and common shares of GODL in connection with the closing of GODL’s first financing. Any shares received would be held by Matador and reflected in its net asset value, subject to the valuation and liquidity limitations that apply to a holding in a private company. The final terms, including the amount and form of consideration payable to Matador, may differ from those currently contemplated. The Licence and the transactions contemplated by it remain subject to Exchange approval and other regulatory requirements, and there can be no assurance that they will be completed or as to the value of any consideration Matador may receive.

The corporate structure by which GODL is established and taken public, and GODL’s legal name, remain under consideration and are subject to tax, regulatory and other considerations. Matador’s intention is to monetize its gold tokenization technology through this arrangement, which reflects the Company’s plans as at the date of this news release. The structure ultimately implemented may differ from the arrangement currently contemplated. In any structure, Matador intends that the value created through the monetization of its gold tokenization technology accrue to Matador shareholders. That value may be retained by Matador and reflected in its net asset value, or delivered to shareholders directly, including by way of a dividend or other distribution of securities. The manner and timing of any distribution to shareholders have not been determined and would be subject to the receipt of any required regulatory, Exchange and shareholder approvals. There can be no assurance that any distribution will be made.

GODL is also planning an equity financing and a subsequent public listing on a Canadian stock exchange. The structure, size, pricing and timing of any such financing and listing have not been determined and would remain subject to market conditions, the receipt of regulatory, exchange and shareholder approvals and the satisfaction of other conditions. There can be no assurance that GODL will complete a financing or obtain a listing on the terms contemplated, within the timeframe contemplated, or at all. This news release does not constitute an offer to sell or the solicitation of an offer to buy any securities of GODL.

Hybrid Issuer Status

Matador is classified by the Exchange as a hybrid technology and investment issuer, which permits the Company to make investments in addition to carrying on its technology activities. Under its investment policy, the Company may invest in any industry, with a focus on the Bitcoin, cryptocurrency and precious metals sectors. Potential investments may include digital assets, securities of public and private companies, precious metals, credit products, derivatives, exchange traded funds and other financial instruments, subject to the restrictions in that policy. Bitcoin remains the Company’s primary treasury asset and the principal focus of its capital allocation.

Leadership

Geoff St. Clair, who had served as Vice President, Finance since the Company’s inception, was appointed Chief Financial Officer effective March 26, 2026. Effective July 16, 2026, Donato Sferra, a co-founder and director of the Company, was appointed Chief Executive Officer, and Deven Soni was appointed Executive Chairman.

Outlook

Management believes that Bitcoin has the potential to serve as a long term store of value and reserve asset, and that its role within the global financial system will continue to develop. Matador is intended to provide investors with a publicly listed vehicle through which to obtain exposure to Bitcoin, with that exposure amplified by the Company’s capital structure and supplemented by its yield generation activities. Management intends to pair that exposure with a lean, low cost operating structure, with the objective of building a durable long term business that can maintain its Bitcoin position through periods of price volatility. These are management’s views and are not a prediction of future Bitcoin prices or a guarantee of the Company’s performance. The price of Bitcoin has historically been highly volatile, and an investment in the Company carries risks that differ from, and may be greater than, those of holding Bitcoin directly.

Donato Sferra, Chief Executive Officer of Matador, commented: “Matador’s capital structure reflects a clear view on Bitcoin, and we are open about the fact that it works in both directions. Over the past year we have put the tools in place to add Bitcoin when our cost of capital allows it, and we have brought the cost of running the Company down to a level that matches the business we are today. We are pleased with that progress, and we believe it leaves Matador in a stronger position to pursue future opportunities while remaining disciplined in how we deploy capital.”

Matador intends to remain focused on the priorities described in this news release: holding Bitcoin as its primary treasury asset, using its capital markets tools when management considers doing so accretive to Bitcoin held per share, generating premium income through its yield generation strategy, maintaining a reduced operating cost base, and advancing the licensing of its gold tokenization technology to GODL. Each of these activities remains subject to market conditions and, where applicable, to regulatory, Exchange and shareholder approvals, and there can be no assurance as to the outcome or timing of any of them. The Company expects to provide further updates as developments warrant.

Media Contact:

Donato Sferra
Chief Executive Officer
Email: donato@matador.network
Phone: 647.496.6282

About Matador Technologies Inc.

Matador Technologies Inc. (TSXV:MATA, OTCQB:MATAF, FSE:IU3) is a publicly traded Bitcoin ecosystem company focused on holding Bitcoin as its primary treasury asset and building products to enhance the Bitcoin network. Matador’s strategy combines strategic Bitcoin accumulation, Bitcoin native product development, and digital asset treasury management, with active participation across blockchain and digital assets infrastructure, all with a focus on disciplined capital allocation and cost efficient treasury management.

With a Bitcoin first strategy, and a clear focus on innovation, Matador is shaping the future of financial infrastructure on Bitcoin.

Visit us online at https://www.matador.network/

Cautionary Statement Regarding Forward Looking Information

NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

This news release does not constitute an offer to sell or the solicitation of an offer to buy any securities in any jurisdiction.

This news release contains “forward looking information” within the meaning of applicable Canadian securities laws. All statements that are not historical facts are forward looking statements, including, without limitation: (i) statements regarding the effect of the Company’s capital structure on its net asset value; (ii) statements regarding management’s views on Bitcoin and the repayment or conversion of the Notes; (iii) statements regarding the Company’s intended use of the ATM Program, the base shelf prospectus and the Facility, including any follow on closings under the Facility and the application of a portion of the net proceeds of qualifying sales to the purchase of Bitcoin as additional collateral; (iv) statements regarding the proposed Preferred Shares, including shareholder approval, final acceptance by the Exchange and any future issuance; (v) statements regarding the Company’s Bitcoin yield generation strategy and future premium income; (vi) statements regarding the Licence and the transactions contemplated by it, including the final corporate structure by which GODL is established and taken public, GODL’s proposed gold treasury strategy, its intended gold yield strategy, its proposed equity financing and public listing, any cash fee or shares Matador may receive, and any distribution of value to Matador shareholders; (vii) statements regarding the Company’s estimated cash operating expenditures and potential further cost reductions; and (viii) statements regarding potential investments within the digital asset ecosystem.

Forward looking information is based on management’s reasonable assumptions at the time such statements are made, including assumptions regarding market conditions; the price and liquidity of Bitcoin; the Company’s ability to access capital markets on acceptable terms; the Company’s continued compliance with the terms of the Facility; the receipt of all required regulatory and shareholder approvals; the continued availability of the ISDA Agreement with Galaxy; the Company’s ability to sustain its cost reduction measures without disruption to its operations; gold market conditions remaining supportive of GODL’s treasury strategy; and the receipt of the regulatory, exchange and shareholder approvals required for the transactions contemplated by the Licence and for GODL’s proposed financing and listing.

Forward looking statements are subject to various risks and uncertainties, including: fluctuations in the price and trading volume of Bitcoin, the effect of which on the Company’s net asset value is magnified by its use of debt; the risk that the price of Bitcoin does not exceed the Company’s acquisition cost and the costs of maintaining the Facility over the term of the Notes; the Company’s obligations under the Facility, including repayment at maturity and the potential consequences of an event of default; the risk that no additional Notes are issued under the Facility; custody and security risks related to digital assets; the timing and amount of future sales under the ATM Program, if any, and resulting dilution to shareholders; the receipt of shareholder approval and final Exchange acceptance of the Preferred Shares; the performance of covered call and other options strategies and counterparty risk in respect of Galaxy; the execution of the Licence on the terms negotiated, or at all; the determination of the final corporate structure by which GODL is established and taken public; the receipt of approvals for, and the completion of, the transactions contemplated by the Licence; the form and value of any consideration received, including the valuation and liquidity of any shares of GODL held by Matador; the unsecured nature of GODL’s payment obligations to Matador; whether any value from the gold business is ultimately distributed to Matador shareholders, and the manner and timing of any such distribution; GODL’s ability to complete its proposed equity financing and to obtain a public listing on a Canadian stock exchange, or at all; the realization of any net yield on GODL’s gold holdings and its reinvestment in additional gold; volatility in the price of gold; the performance and adoption of tokenized gold products; counterparty and custody risk in respect of physical gold held in LBMA accredited vaults and tokenized gold held with digital asset custodians; the risk that the Company’s actual cash operating expenditures differ from management’s estimate, that further cost reductions are not realized, or that reduced reliance on external advisors affects the Company’s operations; risks associated with any investments the Company may make as a hybrid issuer; evolving regulatory treatment of digital assets; and general market conditions.

Forward looking statements are provided to offer information about management’s current expectations and plans as of the date of this news release and may not be appropriate for other purposes. Readers are cautioned not to place undue reliance on such forward looking information. The Company undertakes no obligation to update or revise any forward looking statements, whether as a result of new information, future events, or otherwise, except as required by applicable securities law.

SOURCE: Matador Technologies Inc.

First Half 2026 and Subsequent Commercial and Operational Highlights

  • Completed business combination with NewHold Investment Corp III (“SPAC”) on September 21, 2026 (the “Business Combination”); newcleo’s ordinary shares and warrants commenced trading on the Nasdaq Global Select Market on September 22, 2026 under the symbols “NWCL” and “NWCLW,” respectively
  • The Business Combination generated gross proceeds of approximately $247 million, consisting of approximately $31 million released from the SPAC’s trust account and $216 million from the PIPE financing
  • Raised approximately $18.7 million in additional financing unrelated to the Business Combination since May 2026, bringing total funds raised since newcleo’s founding to over $1 billion
  • Installed the main vessel and turbine for its PRECURSOR non-nuclear 10 MWt demonstration reactor at the ENEA Brasimone Research Center outside Bologna, Italy; completion of construction for PRECURSOR is expected by the end of 2026, with at-scale validation of systems to commence thereafter
  • In partnership with Oklo, selected by the U.S. Department of Energy for advanced negotiations under the Surplus Plutonium Utilization Program
  • Submitted Regulatory Engagement Plans to the U.S. Nuclear Regulatory Commission for the Company’s LFR-AS-200 lead-cooled fast reactor and its planned U.S. mixed-oxide (MOX) fuel manufacturing facility
  • Received notice of an overall opinion of satisfactory compliance from the French Nuclear Safety and Radiation Protection Authority for the proposed safety features for the Company’s planned MOX fuel manufacturing facility in France
  • Announced the acquisition, subject to customary closing conditions, of Bonifait Pesage, a French manufacturer of nuclear-grade scales and precision industrial weighing equipment, augmenting the Company’s vertically integrated capabilities
  • Announced the appointment of Jeffrey Lyash, a nuclear industry veteran and former head of the Tennessee Valley Authority, as Chairman of the Board of Directors
  • Announced the appointment of William D. Magwood as Vice-Chairman of newcleo’s Board of Directors, effective January 1, 2027
  • Announced the hiring of Dustin Greenwood as Vice President of U.S. Operations and Travis Chapman as Director of U.S. Regulatory Affairs and Licensing, strengthening the Company’s growing U.S. team
  • Announced a partnership with SHINE to assess and jointly pursue opportunities relating to nuclear fuel recycling in the United States and European Union
  • On September 10, 2026, newcleo held an Analyst and Investor Day, a recording of which is available on newcleo’s website

First Half 2026 Financial Highlights

  • Generated Revenue from Products and Services of approximately €19.4 million, an increase of approximately 46% over First Half 2025
  • Reported Net Loss of approximately €82.0 million, an increase of approximately 10% over First Half 2025
  • Reported Tangible Capital Expenditures of €25.3 million, an increase of 37% over First Half 2025
  • Reported Selling, General & Administrative expenses of €59.2 million, an approximately 21% increase over First Half 2025
  • Cash & Cash Equivalents as of June 30, 2026 stood at €66.5 million
  • Total ordinary shares outstanding as of the closing date of the Business Combination stood at 281,534,950
  • As of September 30, 2026, preliminary, unaudited Cash & Cash Equivalents for the Company stood at approximately €233 million

LONDON, Oct. 02, 2026 (GLOBE NEWSWIRE) — newcleo plc (Nasdaq: NWCL) (“newcleo” or the “Company”), a pioneer in advanced modular reactor (“AMR”) technology and nuclear fuel manufacturing, today announced its operational and financial results for the six months ended June 30, 2026.

“Becoming a public company is a defining milestone for newcleo, and I want to thank every member of our team for the work that brought us to this point and to reporting our first results as a public company,” said Stefano Buono, Founder and CEO of newcleo. “Access to the public markets strengthens our ability to execute on our mission to deliver a credible, near-term path to advanced nuclear deployment and to close the nuclear fuel cycle. The disciplined engineering, licensing, and partnership work carried out by our more than 900 employees across Europe and the United States will continue to drive newcleo’s progress, and I am excited to work with this incredible team every day.

“Importantly, newcleo is moving quickly down the path to both technical validation and regulatory approval for our facilities. The installation of the main vessel for PRECURSOR, our 10 MWt non-nuclear demonstration reactor at Brasimone, is a development milestone for the LFR technology ahead of planned commercial deployment. Completion of construction for PRECURSOR, which is expected by the end of 2026, and beginning the process of reactor system validation, are the next critical steps in qualifying the technology that will lead to the deployment of our LFR-200 reactor.

“In parallel, pre-licensing for our reactor and MOX fuel facilities in France, Slovakia and the United States, including our ongoing engagement with the U.S. Nuclear Regulatory Commission, has moved forward. Our U.S. growth is a particular focus: our work toward siting at Savannah River, and the broader policy support for nuclear expansion in the U.S., position newcleo to play a meaningful role in meeting U.S. energy demand, including from AI infrastructure. We look forward to updating investors on our progress.”

Commercial & Operational Events

On May 26, newcleo was selected by the U.S. Department of Energy for advanced negotiations under the Surplus Plutonium Utilization Program. The program aims to make designated surplus plutonium material available to industry participants and enable the conversion of those materials into fuel for advanced nuclear reactors, subject to U.S. security, safeguards and material accountability requirements. newcleo’s selection, in partnership with Oklo, continues the companies’ strategic partnership as they work together to develop advanced fuel fabrication infrastructure in the U.S.

On June 16, 2026, the Company announced a partnership with SHINE to collaborate on advancing innovative technologies for the recycling of used nuclear fuel. Under the agreement, the parties will assess how SHINE could supply newcleo with reprocessed materials from the used nuclear fuel of traditional reactors to manufacture MOX fuel, and how SHINE could recycle spent fuel from newcleo’s reactors. The parties also intend to jointly pursue U.S. federal funding opportunities and explore additional opportunities for collaboration across both the U.S. and European Union, where spent fuel stockpiles represent a growing strategic priority to support energy independence.

On June 30, 2026, newcleo announced its entry into an agreement to acquire Bonifait Pesage, a French manufacturer of nuclear-grade scales and precision industrial weighing equipment with a strong customer base in the French nuclear ecosystem. Bonifait Pesage manufactures, installs, calibrates, and maintains weighing equipment, while also providing technical support. Since 2017, the company has held key certifications for the maintenance and verification of weighing systems used in ionizing-radiation environments. The acquisition forms part of newcleo’s vertical integration strategy, pursued since 2023, and is expected to close in the fourth quarter of 2026, subject to customary closing conditions. It is intended to bring critical manufacturing capabilities in-house, secure access to nuclear-grade weighing equipment required for planned MOX fuel manufacturing facilities, reduce supply-chain risk and support equipment customization.

Also subsequent to the first half, newcleo progressed work on the PRECURSOR non-nuclear demonstration reactor with the installation of the main vessel and turbine at ENEA’s Brasimone facility located outside of Bologna, Italy. The 10 MWt non-nuclear demonstration reactor, which is scheduled for completion at the end of 2026, is intended to provide the Company with a fully integrated, representative operating and power generating environment for the Company’s planned commercial reactors. Experimental data obtained through the operation of PRECURSOR is expected to inform the Company’s licensing processes on both sides of the Atlantic, including safety computations, system performance analysis and materials development.

“In the first half of 2026, newcleo continued moving our operations forward, continuing to convert planning into reality,” said Elisabeth Rizzotti, Co-Founder, Deputy-CEO and COO of newcleo. “Our OTHELLO test loop is operating, PRECURSOR is under active construction at Brasimone with major components manufactured and installed by our own vertically integrated subsidiaries, which gives us direct control over cost, schedule, and quality across the supply chain rather than relying on third parties for critical systems. At the same time, our work with trusted partners continues to translate into concrete engineering and commercial work. Each of these efforts, testing, building, manufacturing, and partnering, reflects the same discipline: turning our technology roadmap into physical progress on the ground.”

Regulatory Progress

Subsequent to the end of the first half, on July 17, newcleo announced that it had received from the French Nuclear Safety and Radiation Protection Authority (“ASNR”) an overall satisfactory evaluation for the proposed safety features of its planned MOX fuel manufacturing facility in France. The review by the ASNR offers practical feedback to continue developing the facility’s safety features ahead of a license application and valuable experience to support the licensing process in the U.S. The Company is also progressing through a similar regulatory process for its lead-cooled fast reactor design and is currently awaiting the opinion of the ASNR on the proposed safety features of that design.

On August 6, newcleo announced the submission of a Regulatory Engagement Plan (REP) to the U.S. Nuclear Regulatory Commission (NRC) for its planned mixed-oxide (MOX) fuel fabrication facility, to be located in Aiken, South Carolina. The submission of a REP for the MOX facility followed the submission on July 14 to the NRC of a REP for the Company’s LFR-AS-200 reactor. The submitted REPs set out the proposed framework for newcleo’s pre-application engagement with NRC staff in support of the future licensing of both the MOX facility and the LFR-AS-200 lead-cooled fast reactor. The REPs provide an overview of the Company’s proposed licensing approach and an indicative schedule for technical submissions and interactions with the NRC.

Hiring of Key Personnel

On June 11, newcleo announced the hiring of Dustin Greenwood as Vice President of U.S. Operations and Travis Chapman as Director of U.S. Regulatory Affairs and Licensing to direct and support the Company’s growing presence in the U.S. Both Greenwood and Chapman are experienced nuclear professionals, having worked in the U.S. Navy’s nuclear propulsion program, as well as at leading companies developing advanced reactor and nuclear fuel projects. Dustin Greenwood will lead the development of newcleo’s U.S. operational footprint and oversee execution of the Company’s American projects. He will focus on establishing operational capabilities, building strategic partnerships and supporting delivery of the Company’s U.S. deployment roadmap. Travis Chapman will lead newcleo’s U.S. licensing, permitting and regulatory engagement strategy, overseeing the Company’s interactions with federal regulators and supporting the licensing pathway for newcleo’s advanced reactor and fuel technologies.

On September 9, the Company announced the appointment of Jeffrey Lyash to serve as Chairman of the Board of Directors. Lyash brings more than 40 years of experience spanning engineering, procurement, construction, and operations across the power generation, transmission, and distribution sectors. He most recently served as President and Chief Executive Officer of the Tennessee Valley Authority (TVA), the largest public utility in the United States, where he oversaw generation from coal, nuclear, hydroelectric, natural gas, and renewable sources while driving significant improvements in operating efficiency. Prior to TVA, Lyash served as President and CEO of Ontario Power Generation, where he was responsible for $45 billion in assets and an 11,000-person workforce. He also served as President of Chicago Bridge & Iron’s Power Business Unit, leading engineering, procurement, and construction for multi-billion-dollar generation projects globally.

On September 30, the Company announced the appointment of William D. Magwood as Vice-Chairman of newcleo’s Board of Directors, effective January 1, 2027. Magwood has spent the past decade as Director-General of the OECD Nuclear Energy Agency (NEA), where he works directly with the nuclear regulators and energy ministries of NEA’s member countries. Magwood will step down from his position at the NEA at the end of 2026 prior to assuming his position as newcleo’s Vice-Chairman.

First Half Financial Summary

(Amounts in thousands) For the Six Months Ended
  6/30/2026   6/30/2025
Revenue from Products and Services € 19,429   € 13,347
Gross Profit   6,130     4,154
Other Income 6,554   4,763
Net Loss 81,981   74,293
Capital Expenditures 26,970   19,000
Cash & Cash Equivalents (end of period) 66,540   131,896
       

Revenue from Products and Services increased by approximately €6.1 million, or approximately 46%, for the six months ended June 30, 2026, compared to the six months ended June 30, 2025. The increase was attributable to manufacturing and installation of equipment and spare parts for third parties as well as consultancy services.

Other Income increased by approximately €1.8 million, or 38%, for the six months ended June 30, 2026, compared to the six months ended June 30, 2025. The increase was comprised of grant income and an increase in research and development tax credits, both generated in France and Italy, as well as an increase in other income relating to a one-time project outside the Company’s core operations.

Gross Profit increased by approximately €2.0 million, or 48%, for the six months ended June 30, 2026, compared to the six months ended June 30, 2025. The increase in Gross Profit was due to increases in revenue outpacing increases in costs for the First Half 2026.

Net loss increased by approximately €7.7 million, or 10%, for the six months ended June 30, 2026, compared to the six months ended June 30, 2025, primarily due to higher non-cash share-based payment expense as well as third-party related expenses.

Tangible capital expenditures were approximately €25.3 million for the six months ended June 30, 2026, compared to approximately €18.5 million for the six months ended June 30, 2025. The increase was due to investments in technology and testing experimental facilities.

Selling, General & Administrative expenses were €59.2 million for the six months ended June 30, 2026, compared to approximately €48.9 million for the six months ended June 30, 2025. The increase in SG&A expense was primarily due to increases in share-based payment expense, and increases in other staff costs related to transaction incentives payable on completion.

The Company had Cash & Cash Equivalents available of €66.5 million as of June 30, 2026, compared to €105.3 million as of December 31, 2025 and €131.9 million as of June 30, 2025.

About newcleo

newcleo is an innovative nuclear technology company developing advanced modular reactors and nuclear fuel designed to deliver clean, safe and sustainable energy at competitive costs. newcleo’s technology combines lead-cooled fast reactors with fuel manufactured from recycled nuclear materials, with the aim of providing abundant and reliable electricity and heat to industrial users while enabling the closure of the nuclear fuel cycle. newcleo brings together more than 900 highly skilled employees across Europe and the United States, spanning reactor and fuel design, engineering, and manufacturing. Through a vertically integrated supply chain and a growing network of strategic partnerships, newcleo is working to turn proven scientific and engineering solutions into deployable nuclear energy assets. For more information visit http://www.newcleo.com

Contacts

For Investors and Media:
newcleo@icrinc.com
media@newcleo.com

Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of the U.S. federal securities laws. All statements contained in this press release other than statements of historical fact, including, without limitation, statements regarding newcleo’s development and commercialization of its lead-cooled fast reactor technology, mixed-oxide fuel capabilities and related products and services; the expected timing, cost, performance and benefits of newcleo’s demonstration projects, fuel facilities, reactor deployments and licensing activities; newcleo’s ability to execute its business strategy, develop its technology, obtain required regulatory approvals, permits and licenses, enter into commercial arrangements, achieve its market opportunity and positioning and support the growth of advanced nuclear energy; newcleo’s expectations regarding strategic partnerships, customer demand, project pipeline, revenue streams, capital expenditures and financing needs; and other statements regarding management’s intentions, beliefs, or expectations with respect to newcleo’s future performance, are forward-looking statements. Forward-looking statements are often identified by the use of words such as “anticipate,” “believe,” “continue,” “could,” “develop,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “seek,” “should,” “target,” “will,” “would,” and similar expressions, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements are based on newcleo’s current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such forward-looking statements. You should carefully consider the foregoing factors and the other risks and uncertainties described in other documents filed from time to time by newcleo with the SEC. Additional risks and uncertainties not currently known or that are currently deemed immaterial may also cause actual results to differ materially from those expressed or implied by such forward-looking statements. Readers are cautioned not to put undue reliance on forward-looking statements, and newcleo does not assume any obligation or intend to update or revise these forward-looking statements, each of which is made only as of the date of this press release.

Condensed Consolidated Statements of Profit or Loss and Other Comprehensive Income (Unaudited)
     
  For the six months ended June 30, For the six months ended
June 30 2026
  2026 2025  
  (in thousands of euros unless otherwise stated) Convenience translation into US dollars*
Revenue from Products and Services  19,429 13,347 22,149
Cost of sales (13,299) (9,193) (15,161)
Gross profit 6,130 4,154 6,988
       
Other income 6,554 4,763 7,472
Research and development expenses (34,629) (35,450) (39,477)
Selling, General and Administrative expenses  (59,170) (48,932) (67,454)
Operating loss (81,115) (75,465) (92,471)
       
Loss on disposal of assets (9) (3) (10)
Finance income 353 1,581 402
Finance costs (1,448) (991) (1,650)
Share of loss of associates (83) – (95)
Loss before income tax (82,302) (74,878) (93,824)
       
Income tax benefit 321 585 366
Net loss (81,981) (74,293) (93,458)
       
Other comprehensive income (loss)      
Items that may be subsequently reclassified to profit or loss      
Currency translation differences 198 (144) 226
Other comprehensive income (loss), net of tax 198 (144) 226
       
Total comprehensive loss (81,783) (74,437) (93,232)
       
Net loss attributable to:      
Owners of newcleo plc (81,981) (74,293) (93,458)
Non-controlling interest – – –
       
Total comprehensive loss attributable to:      
Owners of newcleo plc (81,783) (74,437) (93,232)
Non-controlling interest – – –
Net loss per share for loss attributable to the ordinary equity holders:      
Basic and diluted loss per share (0.16) (0.16) (0.18)
       

*Convenience translation into US dollars in thousands (exchange rate as at June 30, 2026: EUR 1 = US$ 1.14).

Note: EPS for the period ended June 30, 2026 is calculated based on the number of shares before the share consolidation. Following the closing of the Business Combination, it would be restated to $(0.34). 

Condensed Consolidated Statements of Financial Position (Unaudited)
       
  June 30, 2026 December 31, 2025 June 30, 2026
 
  (in thousands of euros unless otherwise stated) Convenience translation into US dollars*
ASSETS      
NON-CURRENT ASSETS      
Goodwill 37,281 37,281 42,500
Intangible assets, net 42,760 43,054 48,746
Property, plant and equipment, net 115,999 93,436 132,239
Right-of-use asset  17,665 18,521 20,138
Investments 76 75 87
Investments in associates 31,553 31,635 35,970
Other long-term receivables 34,871 35,207 39,753
Deferred tax assets 3,059 2,176 3,487
TOTAL NON-CURRENT ASSETS 283,264 261,385 322,920
       
CURRENT ASSETS      
Inventories 4,843 5,057 5,521
Short-term investments 2,335 2,291 2,662
Trade receivable, contract and other assets, net  77,768 62,314 88,656
Cash and cash equivalents 66,540 105,270 75,856
TOTAL CURRENT ASSETS 151,486 174,932 172,695
TOTAL ASSETS 434,750 436,317 495,615
       
NON-CURRENT LIABILITIES      
Provisions 4,094 4,170 4,667
Other liabilities 8,932 9,305 10,182
Lease liabilities  14,667 15,537 16,720
Borrowings 15,929 16,306 18,159
Deferred tax liabilities 4,430 4,244 5,050
TOTAL NON-CURRENT LIABILITIES 48,052 49,562 54,778
       
CURRENT LIABILITIES      
Provisions 378 186 431
Trade and other payables 60,055 83,808 68,463
Lease liabilities  3,545 3,250 4,041
Borrowings 2,497 2,583 2,847
TOTAL CURRENT LIABILITIES 66,475 89,827 75,782
TOTAL LIABILITIES 114,527 139,389 130,560
       
EQUITY      
Share capital 5,046 4,739 5,752
Share premium 23,378 562,904 26,652
Other reserves 57,067 51,383 65,057
Retained earnings (accumulated deficits) 234,695 (324,123) 267,552
Equity attributable to owners of newcleo plc 320,186 294,903 365,013
Non-controlling interests 37 2,025 42
TOTAL EQUITY 320,223 296,928 365,055
TOTAL EQUITY AND LIABILITIES 434,750 436,317 495,615

*Convenience translation into US dollars in thousands (exchange rate as at June 30, 2026: EUR 1 = US$ 1.14).

Condensed Consolidated Cash Flow Statement (Unaudited)
     
  For the six months ended June 30 For the six months ended
June 30 2026
  2026 2025
  (in thousands of euros) Convenience translation into US$*
Cash flows from operating activities      
Net loss (81,981) (74,293) (93,458)
Adjustments to reconcile net loss to net cash flows:      
Loss from associates 83 – 95
Finance income (30) (1,476) (34)
Finance costs 1,131 830 1,289
Income tax benefit (321) (585) (366)
Depreciation of property, plant and equipment and right-of-use assets, amortization intangible assets and provisions 8,286 7,397 9,446
Share-based payment expense 21,010 4,975 23,951
Loss on disposals 9 4 10
Other revenues and expenses without effect on cash flow 3 5 3
Changes in working capital:     –
Decrease in inventory 214 94 244
(Increase) in trade receivables, contract and other assets (15,217) (6,781) (17,347)
Increase (decrease) in trade and other payables 13,077 (2,428) 14,908
Income taxes received 49 25 56
Net cash flows used in operating activities (53,687) (72,233) (61,203)
       
Cash flows from investing activities      
Acquisition of intangible assets (1,642) (458) (1,872)
Purchase of property, plant and equipment (25,328) (18,542) (28,874)
Proceeds from maturities of short-term investments – 997 –
Purchase of short-term investments (41) (160) (47)
Interest received from short-term investments 30 1,477 34
Decrease (increase) in loans and deposits made 4 (2) 5
Proceeds from sale of tangible and intangible assets 10 5 12
Net cash flows used in investing activities (26,967) (16,683) (30,742)
       
Cash flows from financing activities      
Proceeds from issues of shares 45,121 – 51,438
Proceeds from issue of shares to non-controlling shareholders – 31,637 –
Repayments of borrowings and lease liabilities  (2,129) (2,535) (2,427)
Interest expenses including interest on lease (1,131) (800) (1,289)
Net cash flows from financing activities 41,861 28,302 47,722
       
Net decrease in cash and cash equivalents (38,793) (60,614) (44,223)
       
Cash and cash equivalents at the beginning of the period 105,270 192,714 120,008
Effect of foreign exchange rate changes 63 (204) 71
Cash and cash equivalents at the end of the period 66,540 131,896 75,856
       

*Convenience translation into US$ in thousands (exchange rate as at June 30, 2026: EUR 1 = US$ 1.14)

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.